Innovating the Pink Eye Treatment Landscape

Leading candidate in Phase 2B for the treatment of Acute Infectious Conjunctivitis.

Enhancing Lives Through Better Vision

Okogen is a clinical stage ophthalmic pharmaceutical company. Our lead product is in clinical trials as a “one stop shop” treatment for all forms of acute infectious conjunctivitis, including bacterial and viral.

Pink eye (conjunctivitis) is when the conjunctiva is irritated by a viral or bacterial infection or allergies. Bacterial and viral conjunctivitis are easily spread from person to person.

– American Academy of Ophthalmology

The current conjunctivitis market is USD $4.2 billion annually and is estimated to reach $6.1 billion by 2031.
85% of this market is driven by antibiotics that are prescribed regardless of etiology of infection
Infectious conjunctivitis represents ~60% of the total conjunctivitis market and 1-2% of all primary care visits worldwide
There are currently no approved treatments for adenoviral conjunctivitis, comprising +90% of all viral ocular infections
Okogen is pursuing a comprehensive treatment for both bacterial and viral conjunctivitis

Latest News & Press

View All News

Press Release

Okogen, Inc., Announces Ophthalmology Industry Veteran Joshua Moriarty as New Chief Executive Officer

March 8, 2022

Press Release

Safe, Effective and Dose Responsive Anti-Viral Activity of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis–Phase 2 Interim Analysis Results from RUBY Clinical Trial

April 29, 2021

Press Release

Okogen Initiates Phase 2 Clinical Trial (RUBY) of OKG-0301 in Patients

January 31, 2019